SAB Biotherapeutics (NASDAQ:SABS) Trading Down 6.7% – Here’s What Happened

SAB Biotherapeutics, Inc. (NASDAQ:SABS)’s share price traded down 6.7% during trading on Friday . The stock traded as low as $1.82 and last traded at $1.82. 70,909 shares were traded during trading, a decline of 58% from the average session volume of 168,294 shares. The stock had previously closed at $1.95.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SABS shares. HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Chardan Capital reiterated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research note on Wednesday, January 29th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Performance

The company has a debt-to-equity ratio of 0.09, a current ratio of 3.69 and a quick ratio of 3.69. The stock’s 50-day moving average price is $3.16 and its 200-day moving average price is $3.02.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in SABS. Northern Trust Corp acquired a new position in SAB Biotherapeutics during the 4th quarter valued at approximately $43,000. Kovitz Investment Group Partners LLC acquired a new position in shares of SAB Biotherapeutics during the third quarter valued at $52,000. Diadema Partners LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth about $114,000. Geode Capital Management LLC increased its holdings in shares of SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock worth $307,000 after acquiring an additional 12,692 shares during the period. Finally, HB Wealth Management LLC increased its holdings in shares of SAB Biotherapeutics by 118.6% in the 4th quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock worth $982,000 after acquiring an additional 128,800 shares during the period. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.